UK Colorectal Cancer Diagnostics Market Insight
Published: 30 May 2026 | Report Format: Electronic (PDF)
The UK colorectal cancer diagnostics market size is rapidly expanding, at a 6.74% CAGR, and the screening programs, molecular testing, AI imaging, precision oncology investments.
UK Colorectal Cancer Diagnostics Market Insights Forecasts to 2035
- The UK Colorectal Cancer Diagnostics Market Size Was Estimated at USD 411.3 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 6.74% from 2025 to 2035
- The UK Colorectal Cancer Diagnostics Market Size is Expected to Reach USD 789.4 Million by 2035
Notable Insights for UK Colorectal Cancer Diagnostics Market
- Screening and early detection diagnostics account for nearly 44% market share in the United Kingdom, driven by screening participation, preventive healthcare awareness, and non-invasive testing adoption, supported by £1.8–£3.2 billion early cancer detection investments nationwide.
- Hospitals and diagnostic laboratories contribute approximately 48% demand share in the United Kingdom, driven by rising testing volumes and pathology expansion, supported by £2.5–£4 billion diagnostic infrastructure investments across NHS systems.
- The United Kingdom healthcare sector invests over £190 billion annually, accelerating precision diagnostics, molecular testing technologies, and AI-powered cancer detection platforms, supported by £6–£10 billion oncology and diagnostics modernization investments nationwide.
- Molecular diagnostics and biomarker testing account for nearly 31% market demand in the United Kingdom, driven by personalized oncology, targeted therapies, and genomic profiling, supported by £2–£4.5 billion precision medicine investments across NHS systems.
Download the eBook (ToC)
Research Methodologies Used to Analyze the UK Colorectal Cancer Diagnostics Market
The United Kingdom colorectal cancer diagnostics market report adopts an advanced research methodology that utilizes almost 74% secondary research data along with approximately 26% primary research data. Secondary research data sources include oncology databases, cancer screenings, health care diagnostics studies, pathology studies, health care statistics from governments, scientific literature, and annual diagnostic technology companies' reports.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the UK colorectal cancer diagnostics market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Colorectal Cancer Diagnostics Market
- Roche Diagnostics
- Abbott Laboratories
- QIAGEN
- Exact Sciences
- Illumina
- Thermo Fisher Scientific
- Guardant Health
- Sysmex Corporation
- Others
Recent Developments:
- In January 2026, the United Kingdom advanced cancer screening and precision medicine initiatives, driven by oncology diagnostics and genomic infrastructure, supported by estimated £3–£5.5 billion NHS investments in early cancer detection and personalized treatment technologies.
- In October 2025, European healthcare markets saw QIAGEN expand molecular colorectal cancer testing and companion diagnostic solutions, enhancing biomarker detection and precision treatment decisions, supported by estimated $1.5–$2.8 billion investments in oncology diagnostics and personalized medicine technologies.
Market Segmentation:
United Kingdom Colorectal Cancer Diagnostics Market, By Test Type
- Fecal Occult Blood Test (FOBT)
- Fecal Immunochemical Test (FIT)
- Colonoscopy
- Flexible Sigmoidoscopy
- Molecular Diagnostics
- Liquid Biopsy
- Others
United Kingdom Colorectal Cancer Diagnostics Market, By Technology
- Immunoassays
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Biomarker Testing
- Digital Pathology
- Others
United Kingdom Colorectal Cancer Diagnostics Market, By End User
- Hospitals
- Diagnostic Laboratories
- Cancer Research Centers
- Specialty Clinics
- Academic Institutions
- Others
United Kingdom Colorectal Cancer Diagnostics Market, By Application
- Screening & Early Detection
- Diagnosis
- Treatment Monitoring
- Recurrence Monitoring
- Others
Expert Views:
The United Kingdom colorectal cancer diagnostics market is anticipated to grow significantly over the years to come due to rising cases of colorectal cancer, increased participation in screening programs, and growing funding for precision oncology techniques.
Author: Govind and Krishna By Spherical Insights and Consulting